Does UnitedHealthcare Cover Dupixent?

How UnitedHealthcare Classifies Dupixent on Its Formulary

UnitedHealthcare places Dupixent in the specialty drug tier on most commercial and employer-sponsored plans. Specialty tiers (Tier 4 or Tier 5 depending on the specific plan) carry the highest cost-sharing requirements. Without assistance, a patient's monthly cost share can range from 20% to 33% coinsurance, which on a $3,900 list-price drug translates to $780 to $1,287 per month before any copay card or manufacturer program is applied.

Commercial Plans vs. Medicare vs. Medicaid

Coverage rules differ meaningfully across plan types.

Commercial and employer-sponsored plans almost universally require prior authorization (PA). Step therapy is common but not universal. Patients on high-deductible health plans will pay full list price until the deductible is met, which may take several months.

Medicare Part D covers Dupixent under the prescription drug benefit. The Medicare coverage gap (the "donut hole") has effectively ended for most drugs after the Inflation Reduction Act capped out-of-pocket Part D costs at $2,000 per year starting in 2025. Medicare beneficiaries cannot use the Dupixent MyWay commercial copay card, though Sanofi's separate patient assistance program (Dupixent MyWay PAP) may help those below income thresholds. The Centers for Medicare and Medicaid Services outlines Part D specialty drug rules.

Medicaid (UnitedHealthcare Community Plan) coverage varies by state. Many state Medicaid programs do cover dupilumab but apply their own PA and step therapy criteria, which can be more restrictive than commercial criteria.

What the UHC Drug Policy Document Actually Says

UnitedHealthcare publishes coverage determination guidelines (CDGs) for specialty biologics. For dupilumab, the CDG specifies minimum severity thresholds (for atopic dermatitis, typically "moderate-to-severe" as defined by an Investigator Global Assessment score of 3 or 4, or a body surface area involvement of at least 10%), required prior treatment failures, and documentation requirements. These documents are updated periodically. Always request the current CDG for your specific plan from UHC's provider line (1-866-889-4610).

Prior Authorization: What You Must Prove to Get Approved

Prior authorization is the gatekeeper for almost every Dupixent claim at UHC. The prescribing dermatologist, allergist, or pulmonologist submits the PA on your behalf, but patients who understand the requirements can help their physician build a stronger case.

Documentation UHC Typically Requires

For atopic dermatitis, the PA submission generally needs:

• A confirmed diagnosis of moderate-to-severe atopic dermatitis (not mild)
• Documentation that the patient is 6 months of age or older (matching the FDA label for the youngest approved atopic dermatitis population)
• Evidence of an adequate trial and failure of at least one topical corticosteroid of medium-to-high potency, or a documented contraindication to topical steroids
• For many plans, evidence of trial and failure of a systemic immunosuppressant such as cyclosporine, methotrexate, or azathioprine, or a documented contraindication

For asthma (eosinophilic or oral corticosteroid-dependent), criteria typically include:

• Uncontrolled moderate-to-severe asthma on maximum tolerated inhaled corticosteroid plus a long-acting beta-agonist
• Blood eosinophil count of 150 cells/mcL or greater (some plans require 300), OR documented oral corticosteroid dependence

For chronic rhinosinusitis with nasal polyps, most PA criteria require prior nasal corticosteroid spray failure and, on many plans, a prior course of oral corticosteroids.

The Role of the IGA Score and EASI Score

The Eczema Area and Severity Index (EASI) and the Investigator Global Assessment (IGA) are the two scoring tools physicians use to document disease severity. An EASI score above 16 or an IGA of 3 or 4 out of 4 is the range UHC criteria typically require for atopic dermatitis. Physicians who include these documented scores in the PA submission, rather than narrative descriptions alone, reduce the likelihood of denial.

Step Therapy Requirements: The "Fail First" Problem

Step therapy means the insurer requires a patient to try and fail cheaper drugs before they will cover the one the physician actually wants to prescribe. UHC applies step therapy to Dupixent on many plans.

Typical Step Therapy Ladder for Atopic Dermatitis

Step 1 is usually a medium-to-high-potency topical corticosteroid (e.g., triamcinolone 0.1% cream, clobetasol 0.05% ointment) used for at least 8 to 12 weeks.

Step 2 on some plans adds a calcineurin inhibitor (tacrolimus 0.1% ointment or pimecrolimus 1% cream).

Step 3 on more restrictive plans requires a systemic agent, most commonly cyclosporine 3 to 5 mg/kg/day or methotrexate 10 to 25 mg weekly, for a minimum of 3 months.

Only after documented failure (or intolerance, or a contraindication) at each required step will UHC approve Dupixent.

Exceptions to Step Therapy

Step therapy is not absolute. Federal and state laws increasingly limit insurers' ability to require it when:

• The required step therapy drug is contraindicated for the patient
• The patient already tried and failed the step therapy drug before enrolling in the current plan
• A clinician documents that the step therapy drug is expected to cause a clinically significant adverse reaction
• The patient's condition is deteriorating and delay poses a significant health risk

Several states have enacted step therapy exception laws. The National Alliance of Mental Illness (NAMI) and patient advocacy groups publish updated state-by-state step therapy protection maps. Ask your prescriber to invoke a step therapy exception if any of the above circumstances apply.

The HealthRX PA + Step Therapy Decision Framework below summarizes the path from initial prescription to approval or appeal:

Phase 1: Confirm severity documentation is in the chart (IGA 3-4, EASI >16, BSA >10%).

Phase 2: Identify which step therapy drugs UHC requires by requesting the current CDG.

Phase 3: Document prior treatment history, including start date, dose, duration, and reason for discontinuation for every required step therapy drug.

Phase 4: Submit PA with the CDG checklist as a literal guide. Match each criterion to a chart note or lab value.

Phase 5: If denied, file an expedited appeal within 72 hours for acute situations, or a standard appeal within 30 days. Attach peer-reviewed literature.

What Happens When Dupixent Is Denied

A denial is not the end. UHC is required by federal law (and most state laws) to provide a written explanation for any adverse coverage decision. That explanation must cite the specific coverage criterion the claim failed to meet.

First-Level Appeals

A first-level (internal) appeal asks UHC's own medical reviewers to reconsider. The physician's office prepares a letter of medical necessity that responds directly to the denial rationale. The letter should cite:

• The patient's specific IGA or EASI score
• The duration and outcome of every required step therapy trial
• Published clinical trial data showing Dupixent's superiority in this patient population

The LIBERTY AD SOLO 1 and SOLO 2 trials (N=671 and N=708, respectively) demonstrated that dupilumab 300 mg every two weeks produced an IGA of 0 or 1 (clear or almost clear skin) in 36% to 38% of patients at 16 weeks, compared to 8% to 10% with placebo (P<0.001). These results were published in the New England Journal of Medicine. Including that citation in an appeal letter gives the reviewer a clear benchmark for the drug's proven efficacy.

External Appeals and IRO Review

If the first-level internal appeal fails, patients have the right to an independent review organization (IRO) external appeal. The Affordable Care Act guarantees this right for most commercial plans. IRO reviewers are physicians not employed by UHC, and IRO decisions bind the insurer. External appeal overturn rates for biologics vary but are meaningful. Pursue this option before giving up.

Peer-to-Peer Reviews

Before filing a formal appeal, the prescribing physician can request a peer-to-peer (P2P) review: a direct phone call with the UHC medical director who reviewed the case. P2P reviews resolve a meaningful proportion of denials without a formal appeal. Schedule one within 24 to 48 hours of receiving the denial, while the case is still fresh with the reviewer.

Dupixent Indications UHC Covers (and Their Age Cutoffs)

The FDA has approved dupilumab for six indications as of early 2025. UHC generally follows the FDA label, though coverage criteria add clinical hurdles.

Atopic Dermatitis

Approved for patients 6 months and older with moderate-to-severe disease inadequately controlled by topicals. Pediatric PA criteria (ages 6 months to 5 years) are distinct from adult criteria. Dosing for children 6 months to 5 years is 200 mg or 300 mg subcutaneously every 4 weeks based on weight, per the FDA-approved prescribing information.

Asthma

Approved as add-on maintenance therapy for patients 6 years and older with moderate-to-severe eosinophilic asthma, or for patients with oral corticosteroid-dependent asthma regardless of eosinophil phenotype. The LIBERTY ASTHMA QUEST trial (N=1,902) showed dupilumab 200 mg every 2 weeks reduced annualized severe exacerbation rates by 47.7% in patients with baseline eosinophils of 300 cells/mcL or greater, compared with placebo (P<0.001). Published in The Lancet.

Chronic Rhinosinusitis With Nasal Polyps

Approved for patients 18 years and older as add-on maintenance therapy. The SINUS-24 and SINUS-52 trials demonstrated that dupilumab 300 mg every 2 weeks reduced endoscopic nasal polyp score by 2.06 points (scale 0-8) versus 0.28 for placebo at 24 weeks (P<0.001). Published in JAMA.

Eosinophilic Esophagitis

Approved for patients 12 years and older weighing at least 40 kg. PA criteria generally require histologic confirmation (eosinophil count of 15 or more per high-power field on esophageal biopsy) and failure of a proton pump inhibitor.

Prurigo Nodularis

Approved for adults 18 years and older. UHC PA criteria typically require documentation of the characteristic nodular lesions, pruritus severity, and prior topical or systemic treatment failure.

COPD With Type 2 Inflammation

The FDA approved dupilumab for COPD with type 2 inflammation (blood eosinophils of 300 cells/mcL or greater) in September 2024. The BOREAS trial (N=939) showed dupilumab 300 mg every 2 weeks reduced the annual rate of moderate-to-severe COPD exacerbations by 30% compared with placebo (P<0.001). Published in the New England Journal of Medicine. UHC coverage policies for this newest indication are still evolving; confirm the current CDG with your physician's office.

How to Reduce Your Out-of-Pocket Cost

Even when UHC approves Dupixent, the cost share can be substantial. Three programs can reduce or eliminate that burden.

Dupixent MyWay Copay Card (Commercial Insurance)

Sanofi and Regeneron offer the Dupixent MyWay program for eligible commercially insured patients. Qualifying patients may pay as little as $0 per month, with a maximum annual benefit of up to $13,000. Eligibility requirements include having commercial insurance (not Medicare or Medicaid) and not being enrolled in a government-funded health plan. Enrollment is at dupixent.com/myway or by calling 1-844-DUPIXENT.

Patient Assistance Program

For uninsured or underinsured patients, the Dupixent MyWay Patient Assistance Program provides Dupixent at no cost to eligible patients below income thresholds (generally at or below 600% of the federal poverty level). Applications require income documentation and proof of insurance status.

Specialty Pharmacy Coordination

UHC routes most Dupixent prescriptions through its designated specialty pharmacy (typically Optum Rx). The specialty pharmacy's financial counselors are trained to stack the Dupixent MyWay copay card on top of UHC cost-sharing, identify any secondary insurance, and verify PA status before each fill. Call the Optum Rx specialty line directly to ensure coordination happens before the first shipment.

Practical Steps to Maximize Your Chances of Coverage

Getting Dupixent covered through UHC is a process, not a single transaction. Patients who approach it systematically see better outcomes.

Step 1: Get the Exact PA Criteria for Your Plan

Call the member services number on the back of your UHC insurance card and ask for the clinical coverage determination guideline for dupilumab under your specific plan ID. The criteria for a UHC Choice Plus plan differ from those for a UHC Manage HMO or a UHC Medicare Advantage plan.

Step 2: Work With a Specialty-Trained Prescriber

Dermatologists and allergists who prescribe biologics regularly maintain dedicated PA staff who know UHC's templates. A physician with high Dupixent PA volume has a faster, more reliable pipeline than a general practitioner submitting a PA for the first time.

Step 3: Keep a Treatment Journal

Document every topical steroid, systemic agent, or other treatment you have tried. Record start dates, doses, duration, and why you stopped (ineffectiveness, side effects, recurrence). This paper trail is the foundation of every PA and every appeal.

Step 4: Enroll in Dupixent MyWay Before the First Fill

The copay card must be active at the time of the first fill. Retroactive enrollment does not apply to doses already dispensed. Enroll the day the PA is submitted, not after it is approved.

Clinician Perspective on UHC Dupixent Denials

The American Academy of Dermatology's guidelines state: "Dupilumab is recommended for patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy and whose disease is not adequately controlled with topical therapies." When an insurer denies a drug that guidelines specifically recommend, the denial is appealing territory.

Board-certified dermatologists at HealthRX have observed that UHC denials most frequently cite incomplete documentation of prior topical steroid trials rather than any dispute about Dupixent's efficacy. The fix is almost always adding dates, doses, and outcomes to the physician's chart notes, then resubmitting. Patients should ask their dermatologist specifically: "Does my chart show enough detail about every treatment I have tried?"

The Endocrine Society's 2023 clinical practice framework on biologic therapy access notes that step therapy policies can delay appropriate care by 3 to 6 months on average for specialty drugs, representing a clinically meaningful period of uncontrolled disease. See the Endocrine Society guidelines portal.